HSP90AA1 and cancer: It was demonstrated that ganetespib can inhibit HSP90 in a dose-dependent manner, resulting in anti-cancer activity and the strong radiosensitization of HCC cell lines by affecting important cellular signaling pathways, causing cell cycle arrest in more radiosensitive phases of the cell cycle, and inhibiting DNA repair mechanisms.